AIM: To evaluate the comfort and visual performance of Rose K2 soft contact lenses in patients with keratoconus.METHODS: Fifty eyes of 50 participants were included in this cross-sectional study.Each participant received a full ophthalmologic examination involving refraction,uncorrected visual acuity (UCVA),best spectacle corrected visual acuity (BCVA),slit-lamp biomicroscopy-fundoscopy,break-up time (BUT),corneal topography,and contrast sensitivity.After contact lens was fitted best contact lens corrected visual acuity (BCLCVA),contrast sensitivity,and comfort rating via visual analogue scales (VAS) were performed.RESULTS: The mean age was 26.2±6.0 (range: 16 to 39)y.The mean logMAR UCVA,BCVA,and BCLCVA with Rose K2 soft (in order) were 0.61±0.37 (range: 0.15-1.3),0.42±0.32 (range: 0-1.3),and 0.18±0.20 (range: 0-1.3).There were significant increases in visual acuities with contact lenses (P < 0.05).The mean contrast sensitivity scores were significantly better with both contact lens in mesopic and photopic conditions (P <0.05).The mean VAS score was 8.02±1.64 (range: 5-10) for Rose K2 soft.CONCLUSION: Rose K2 soft contact lens can improve visual acuity,contrast sensitivity with comfort in patients with keratoconus.

PURPOSE: To evaluate the outcomes of 5-year ranibizumab treatment in neovascular age-related macular degeneration (nAMD) in a single center and real life clinical setting. METHODS: The records of nAMD patients who were treated with ranibizumab between January 2010 and June 2011 were retrospectively reviewed. Patients who completed 5 years of follow-up were included. Main outcome measures were change in best-corrected visual acuity, central retinal thickness, and visit and injection numbers. RESULTS: Forty-four eyes of 37 patients were included. Mean best-corrected visual acuity decreased from 0.82 ± 0.69 to 1.11 ± 0.65 logarithm of minimal angle of resolution after 5 years. Twenty-four eyes (54.5%) had visual acuity loss ≥3 lines, and 20 eyes (45.5%) had stable or improved vision (loss <3 lines, remained stable, or gained ≥1 line) at month 60. The mean total number of visits was 25.3 ± 5.8 (range, 14 to 42), and the mean total number of injections was 12.6 ± 6.4 (range, 3 to 26) at month 60. CONCLUSIONS: Half of the ranibizumab-treated nAMD patients maintained their vision during the 5 years of follow-up. Visit and injection numbers were found to be lower than in prospective studies, reflecting a real world clinical practice.
Follow-Up Studies ; Humans ; Macular Degeneration* ; Outcome Assessment (Health Care) ; Prospective Studies ; Ranibizumab* ; Retinaldehyde ; Retrospective Studies ; Visual Acuity